Literature DB >> 17957077

The risks and benefits of radiotherapy with massive endoprosthetic replacement.

L M Jeys1, J S Luscombe, R J Grimer, A Abudu, R M Tillman, S R Carter.   

Abstract

Between 1966 and 2001, 1254 patients underwent excision of a bone tumour with endoprosthetic replacement. All patients who had radiotherapy were identified. Their clinical details were retrieved from their records. A total of 63 patients (5%) had received adjunctive radiotherapy, 29 pre-operatively and 34 post-operatively. The mean post-operative Musculoskeletal Tumor Society scores of irradiated patients were significantly lower (log-rank test, p = 0.009). The infection rate in the group who had not been irradiated was 9.8% (117 of 1191), compared with 20.7% (6 of 29) in those who had pre-operative radiotherapy and 35.3% (12 of 34) in those who radiotherapy post-operatively. The infection-free survival rate at ten years was 85.5% for patients without radiotherapy, 74.1% for those who had pre-operative radiotherapy and 44.8% for those who had post-operative radiotherapy (log-rank test, p < 0.001). The ten-year limb salvage rate was 89% for those who did not have radiotherapy and 76% for those who did (log-rank test, p = 0.02). Radiotherapy increased the risk of revision (log-rank test, p = 0.015). A total of ten amputations were necessary to control infection, of which nine were successful. Radiotherapy may be necessary for the treatment of a bone sarcoma but increases the risk of deep infection for which amputation may be the only solution.

Entities:  

Mesh:

Year:  2007        PMID: 17957077     DOI: 10.1302/0301-620X.89B10.19233

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  9 in total

Review 1.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

2.  What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors?

Authors:  C Theil; J Röder; G Gosheger; N Deventer; R Dieckmann; D Schorn; J Hardes; D Andreou
Journal:  Clin Orthop Relat Res       Date:  2019-12       Impact factor: 4.176

Review 3.  Silver-coated megaprostheses: review of the literature.

Authors:  Tom Schmidt-Braekling; Arne Streitbuerger; Georg Gosheger; Friedrich Boettner; Markus Nottrott; Helmut Ahrens; Ralf Dieckmann; Wiebke Guder; Dimosthenis Andreou; Gregor Hauschild; Burkhard Moellenbeck; Wenzel Waldstein; Jendrik Hardes
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-06

Review 4.  [Management of complications in megaprostheses].

Authors:  J Hardes; H Ahrens; G Gosheger; M Nottrott; R Dieckmann; M-P Henrichs; A Streitbürger
Journal:  Unfallchirurg       Date:  2014-07       Impact factor: 1.000

5.  [Modular tumor prostheses of the humerus].

Authors:  P T Funovics; M Dominkus
Journal:  Orthopade       Date:  2010-10       Impact factor: 1.087

Review 6.  [Current results of tumour endoprosthetics in adolescents and adults].

Authors:  J Hardes; W Guder; M Dudda; M Nottrott; L-E Podleska; A Streitbürger
Journal:  Orthopade       Date:  2019-09       Impact factor: 1.087

7.  Is a single dose of preoperative antibiotic therapy effective for patients treated with megaendoprosthesis after metastatic bone tumour resection?

Authors:  M Kiran; J Alsousou; N Dalal; P Ralte; G Kumar; B Kapoor
Journal:  Musculoskelet Surg       Date:  2021-01-05

8.  What Is the Implant Survivorship and Functional Outcome After Total Humeral Replacement in Patients with Primary Bone Tumors?

Authors:  Kristian Nikolaus Schneider; Jan Niklas Bröking; Georg Gosheger; Timo Lübben; Jendrik Hardes; Dominik Schorn; Maria Anna Smolle; Christoph Theil; Dimosthenis Andreou
Journal:  Clin Orthop Relat Res       Date:  2021-08-01       Impact factor: 4.755

9.  Limb salvage in musculoskeletal oncology: Recent advances.

Authors:  Ajay Puri
Journal:  Indian J Plast Surg       Date:  2014-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.